Unternehmensportrait
Ryvu Therapeutics is developing therapeutics that address clinical limitations of current treatments in oncolog.
Their lead candidate, RVU120, is a selective CDK8/CDK19 kinase inhibitor with potential for development in hematological malignancies and solid tumors, currently in Phase 1b study for the treatment of acute myeloid leukemia and myelodysplastic syndrome, and Phase I/II for the treatment of r/r metastatic or advanced solid tumors. SEL24 (MEN1703) is a dual PIM/FLT3 kinase inhibitor licensed to the Menarini Group, in Phase 2 clinical development for the treatment of acute myeloid leukemia.
Vorstand & Aufsichtsrat
| Vorstandsvorsitzender |
| Paweł Przewięźlikowski |
| Vorstand |
| Vatnak Vat-Ho, Hendrik Nogai, Kamil Sitarz, Krzysztof Brzózka |
| Aufsichtsrat |
| Piotr Romanowski, Tadeusz Wesołowski, Rafał Chwast, Axel Glasmacher, Jarl Jungnelius, Thomas Turalski |
Unternehmensinformationen
| Name: |
RYVU THERAPEUTICS S.A. |
| Adresse: |
Leona Henryka Sternbacha 2,30-394 Kraków |
| Telefon: |
+48 12 314 02 00 |
| Fax: |
+48 12 297 47 01 |
| E-Mail: |
ryvu@ryvu.com
|
| Internet: |
https://ryvu.com/ |
| Industrie: |
Biotechnologie |
| Sektor: |
Biotechnologie |
| Sub-Sektor: |
- |
| Ende des Finanzjahres: |
31.12 |
| Streubesitz: |
74,30% |
| IPO Datum: |
14.07.2011 |
Investor Relations
| Name: |
- |
| IR Telefon: |
- |
| IR Fax: |
- |
| IR E-Mail: |
ir@ryvu.com
|
